Business Wire

Modra Pharmaceuticals Appoints Two New Supervisory Board Members Adding Significant Experience in Corporate and Clinical Development

AMSTERDAM--(BUSINESS WIRE)--Modra Pharmaceuticals (“Modra”) today announced the appointment of Hemanshu Shah, Ph.D., MBA and Klaus Schollmeier, Ph.D. to its supervisory board. The new members bring ...
Business Wire

Modra Pharmaceuticals Presents Positive Phase IIb Results for ModraDoc006/r, a Boosted Oral Taxane for Patients with Metastatic Prostate Cancer, at 2022 ASCO GU Annual Meeting

AMSTERDAM--(BUSINESS WIRE)--Modra Pharmaceuticals (“Modra”) today announced positive data from its Phase IIb trial evaluating its boosted oral taxane therapeutic, ModraDoc006/r, in patients with ...
FiercePharma

Modra, taking a leaf out of the Paxlovid playbook, validates oral delivery of chemotherapy in the clinic

Modra Pharmaceuticals’ oral docetaxel has performed comparably to the intravenous incumbent in a phase 2b clinical trial, emboldening the company to start work on a pivotal study. Docetaxel is given ...
DutchNews.NL

Modra Pharmaceuticals Announces U.S. Patent Issuance for ModraDoc006/r

AMSTERDAM–(BUSINESS WIRE)–Modra Pharmaceuticals (“Modra”) today announced that the U.S. Patent and Trademark Office (USPTO) has issued to Modra U.S. Patent No. 11,571,408, covering the use of its oral ...
DutchNews.NL

Modra Pharmaceuticals Presents Preliminary Data from Phase IIb Trial of ModraDoc006/r in Metastatic Prostate Cancer at 2021 ASCO GU Annual Meeting

AMSTERDAM–(BUSINESS WIRE)–Modra Pharmaceuticals (“Modra”) today announced preliminary data from its ongoing Phase IIb trial for lead candidate, ModraDoc006/r, a proprietary oral therapeutic based on ...